Name | Number of supported studies | Average coverage | |
---|---|---|---|
oligodendrocyte | 5 studies | 24% ± 6% | |
adipocyte | 3 studies | 16% ± 1% | |
dendritic cell | 3 studies | 17% ± 1% | |
macrophage | 3 studies | 17% ± 3% | |
astrocyte | 3 studies | 26% ± 8% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 712.70 | 1445 / 1445 | 100% | 9.26 | 183 / 183 |
kidney | 100% | 1174.31 | 89 / 89 | 100% | 23.66 | 901 / 901 |
ovary | 100% | 731.10 | 180 / 180 | 100% | 11.10 | 430 / 430 |
stomach | 100% | 662.47 | 359 / 359 | 100% | 7.67 | 286 / 286 |
skin | 100% | 700.97 | 1809 / 1809 | 100% | 16.21 | 471 / 472 |
lung | 100% | 858.80 | 578 / 578 | 100% | 10.55 | 1152 / 1155 |
breast | 100% | 892.97 | 459 / 459 | 100% | 9.18 | 1114 / 1118 |
intestine | 100% | 657.20 | 966 / 966 | 100% | 7.58 | 525 / 527 |
bladder | 100% | 811.29 | 21 / 21 | 99% | 9.97 | 501 / 504 |
uterus | 100% | 843.76 | 170 / 170 | 99% | 9.89 | 456 / 459 |
prostate | 100% | 776.35 | 245 / 245 | 99% | 7.94 | 497 / 502 |
pancreas | 100% | 527.99 | 328 / 328 | 99% | 9.35 | 176 / 178 |
thymus | 100% | 701.69 | 653 / 653 | 99% | 6.65 | 596 / 605 |
brain | 98% | 353.45 | 2594 / 2642 | 100% | 10.46 | 705 / 705 |
liver | 100% | 454.92 | 226 / 226 | 98% | 9.94 | 397 / 406 |
adrenal gland | 100% | 960.28 | 258 / 258 | 95% | 6.60 | 219 / 230 |
adipose | 100% | 869.96 | 1204 / 1204 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 100% | 10.59 | 80 / 80 |
lymph node | 0% | 0 | 0 / 0 | 100% | 10.87 | 29 / 29 |
muscle | 100% | 1188.97 | 803 / 803 | 0% | 0 | 0 / 0 |
spleen | 100% | 956.47 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 9.92 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 3.01 | 1 / 1 |
blood vessel | 100% | 673.50 | 1333 / 1335 | 0% | 0 | 0 / 0 |
peripheral blood | 99% | 1129.95 | 921 / 929 | 0% | 0 | 0 / 0 |
heart | 99% | 501.88 | 850 / 861 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0006303 | Biological process | double-strand break repair via nonhomologous end joining |
GO_2001033 | Biological process | negative regulation of double-strand break repair via nonhomologous end joining |
GO_0033152 | Biological process | immunoglobulin V(D)J recombination |
GO_0035861 | Cellular component | site of double-strand break |
GO_0005737 | Cellular component | cytoplasm |
GO_0005634 | Cellular component | nucleus |
GO_0005515 | Molecular function | protein binding |
Gene name | CYREN |
Protein name | Cell cycle regulator of NHEJ Cell cycle regulator of non-homologous end joining (Cell cycle regulator of NHEJ) (Modulator of retrovirus infection homolog) |
Synonyms | MRI C7orf49 |
Description | FUNCTION: Cell-cycle-specific regulator of classical non-homologous end joining (NHEJ) of DNA double-strand break (DSB) repair, which can act both as an activator or inhibitor of NHEJ, depending on the cell cycle phase . Acts as a regulator of DNA repair pathway choice by specifically inhibiting classical NHEJ during the S and G2 phases, thereby promoting error-free repair by homologous recombination during cell cycle phases when sister chromatids are present . Preferentially protects single-stranded overhangs at break sites by inhibiting classical NHEJ, thereby creating a local environment that favors homologous recombination . Acts via interaction with XRCC5/Ku80 and XRCC6/Ku70 . In contrast, acts as an activator of NHEJ during G1 phase of the cell cycle: promotes classical NHEJ in G1 phase cells via multivalent interactions that increase the affinity of DNA damage response proteins for DSB-associated chromatin. Also involved in immunoglobulin V(D)J recombination (By similarity). May also act as an indirect regulator of proteasome (By similarity). . |
Accessions | Q9BWK5 ENST00000393114.8 [Q9BWK5-1] ENST00000424142.5 [Q9BWK5-3] ENST00000617987.1 [Q9BWK5-4] ENST00000430372.1 C9JKC7 ENST00000483029.2 [Q9BWK5-3] ENST00000620897.4 [Q9BWK5-3] |